189 related articles for article (PubMed ID: 26295181)
1. De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years.
Zavos G; Moris D; Kostakis ID; Vernadakis S; Bokos J; Zavvos V; Lionaki S; Boletis J
Exp Clin Transplant; 2015 Aug; 13(4):313-8. PubMed ID: 26295181
[TBL] [Abstract][Full Text] [Related]
2. Early versus late acute antibody-mediated rejection in renal transplant recipients.
Dörje C; Midtvedt K; Holdaas H; Naper C; Strøm EH; Øyen O; Leivestad T; Aronsen T; Jenssen T; Flaa-Johnsen L; Lindahl JP; Hartmann A; Reisæter AV
Transplantation; 2013 Jul; 96(1):79-84. PubMed ID: 23632391
[TBL] [Abstract][Full Text] [Related]
3. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
[TBL] [Abstract][Full Text] [Related]
4. De Novo Malignant Neoplasms in Renal Transplant Patients.
Yılmaz Akçay E; Tepeoğlu M; Özdemir BH; Deniz E; Börcek P; Haberal M
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):100-105. PubMed ID: 27805524
[TBL] [Abstract][Full Text] [Related]
5. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
[TBL] [Abstract][Full Text] [Related]
6. Malignancy following renal transplantation.
Yang TC; Shu KH; Cheng CH; Wu MJ; Lian JD
Zhonghua Yi Xue Za Zhi (Taipei); 1998 May; 61(5):281-8. PubMed ID: 9650432
[TBL] [Abstract][Full Text] [Related]
7. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
8. Low prevalence of BK virus nephropathy on nonprotocol renal biopsies in Iranian kidney transplant recipients: one center's experience and review of the literature.
Soleymanian T; Rasulzadegan MH; Sotoodeh M; Ganji MR; Naderi G; Amin M; Saddadi F; Hakemi M; Najafi I
Exp Clin Transplant; 2010 Dec; 8(4):297-302. PubMed ID: 21143095
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
[TBL] [Abstract][Full Text] [Related]
10. [De novo malignancy following renal transplantation].
Suzuki S; Osaka Y; Nakai I; Yasumura T; Omori Y; Oka T
Nihon Geka Gakkai Zasshi; 1994 Nov; 95(11):834-7. PubMed ID: 7830710
[TBL] [Abstract][Full Text] [Related]
11. Malignancy in renal transplant recipients: a single-center experience in Thailand.
Ruangkanchanasetr P; Lauhawatana B; Leawseng S; Kitpanich S; Lumpaopong A; Thirakhupt P
J Med Assoc Thai; 2012 May; 95 Suppl 5():S12-6. PubMed ID: 22934439
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in renal transplant recipients.
Chuang CH; Chien YS; Cheng YT; Chen YT; Hu TH; Hsieh H
Transplant Proc; 2008 Sep; 40(7):2392-4. PubMed ID: 18790244
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
Azarpira N; Aghdaie MH; Malekpour Z
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
[TBL] [Abstract][Full Text] [Related]
14.
Moris D; Kakavia K; Argyrou C; Garmpis N; Bokos J; Vernadakis S; Diles K; Sotirchos G; Boletis J; Zavos G
Anticancer Res; 2017 Feb; 37(2):773-779. PubMed ID: 28179329
[TBL] [Abstract][Full Text] [Related]
15. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
16. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.
Kelly DM; Emre S; Guy SR; Miller CM; Schwartz ME; Sheiner PA
Cancer; 1998 Sep; 83(6):1237-43. PubMed ID: 9740091
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignancy with long-term immunosuppression in renal transplant recipients.
Agraharkar ML; Cinclair RD; Kuo YF; Daller JA; Shahinian VB
Kidney Int; 2004 Jul; 66(1):383-9. PubMed ID: 15200447
[TBL] [Abstract][Full Text] [Related]
18. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
19. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
20. Reductions in immunosuppression after haematological or solid organ cancer diagnosis in kidney transplant recipients.
Hope CM; Krige AJ; Barratt A; Carroll RP
Transpl Int; 2015 Nov; 28(11):1332-5. PubMed ID: 26174703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
